Treatment of early stages of Hodgkin's lymphoma with regard to quality assurance;Behandlung früher stadien des Hodgkin-lymphoms unter dem aspekt der qualitätssicherung

Onkologe

Volumn 11, Issue 9, 2005, Pages 924-932

  Eich, H T ^a   Hansemann, K ^a   Muller R P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Competence network malignant lymphoma; Extended field radiotherapy; Hodgkin's lymphoma; Involved field radiotherapy; Quality assurance

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; HODGKIN DISEASE; HUMAN; PROSPECTIVE STUDY; QUALITY CONTROL; RADIOSENSITIVITY; SIDE EFFECT; STANDARDIZATION;

EID: 24944478525     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-005-0923-4     Document Type: Article

References (24)

1. Tubiana M, Henry-Amar M, Carde (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 73:47-56
2. Rosenberg SA, Kaplan HS (1970) Hodgkin's disease and other malignant lymphoma. Calif Med 113:23-38
3. Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 11:5-22
4. Noordijk EM, Carde P, Hagenbeek A et al. (1997) Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials "H7-VF","H7-F" and "H7-U". Int J Radiat Oncol Biol Phys 39:173 (Abstract)
5. Noordijk EM, Mellink WAM, Carde P, Ferme C, Eghbali H, Henry-Amar M (1998) Very favorable Hodgkin's disease: Does it really exist? Leuk Lymphoma 29:49
6. Carde P, Noordijk E, Hagenbeek A (1997) Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's disease: the EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 16:13 (Abstract)
7. Carde P, Burgers JM, Henry-Amar M et al. (1988) Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors [see comments]. J Clin Oncol 6:239-252
8. Dühmke E, Diehl V, Löffler M et al. (1996) Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305-310
9. Dühmke E, Franklin J, Pfreundschuh M et al. (2001) Low-dose radiation is sufficient for the noninvolved extended field treatment in favourable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905-2914
10. Sieber M, Brillant C, Josting A et al. (2003) Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: Final results of the German Hodgkin's Lymphoma Study Group trial HD7. Onkologie 26 [Suppl 5]:20 (Abstract)
11. Shore T, Nelson N, Weinerman B (1990) A meta-analysis of stages I and II Hodgkin's disease. Cancer 65:1155-1160
12. Specht L, Gray, ML, Clarke MJ, Peto R (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16:830-843
13. Bates NP, Williams MV, Bessel EM, Vaughan Hudson G, Vaughan Hudson B (1994) Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 12:288-296
14. Hagenbeek A, Carde P, Noordijk E et al. (1997) Prognostic factor tailored treatment of early stage Hodgkin's disease. Results from a prospective randomized phase III clinical trial in 762 patients (H7 study). Blood 90 [Suppl 1]:Abstract 2603
15. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA (1988) Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6:1822-1831
16. Radford JA, Cowan RA, Ryder WDJ (1996) Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage (CS) IA/IIA Hodgkin's disease. Results of a randomised pilot study. Ann Oncol 7: Abstract 66
17. Canellos GR Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478-1484
18. Duggan D, Petroni G, Johnson J et al. (1997) MOPP/ABV versus ABVD for advanced Hodgkin's disease - a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 16:43 (Abstract)
19. Trümper L, Pfreundschuh M (2000) The role of treatment duration in chemotherapy regimens for the treatment of malignant diseases. Strahlenther Onkol 176:466-471
20. Eich HT, Müller R-P, Ansen S et al. (2004) Neue Therapiestrategien des Morbus Hodgkin in Kooperation von Radioonkologie und Internistischer Onkologie. Röntgenpraxis 51:114-124
21. Biti G, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378-382
22. Eich HT, Staar S, Gossmann A et al. (2004) Centralized radiation oncological review of cross-sectional imaging of Hodgkin's disease leads to significant changes of the required involved field - results of a quality assurance program of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 58:1121-1127
23. Eich HT, Müller R-P, Schneeweiss A et al. (2004) Initiation of a teleradiotherapeutic network for patients in German lymphoma studies. Int J Radiat Oncol Biol Phys 58:805-808
24. Eich HT, Haverkamp U, Engert A et al. (2005) Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's Lymphoma - a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys (in press)